TransCode (RNAZ) Schedule 13G/A: Anson Group Reports 27,125 Shares
TransCode Therapeutics, Inc. Schedule 13G/A filed by Anson-related parties reports collective beneficial ownership of 27,125 shares of TransCode common stock, representing 0.1% of the outstanding class when including shares underlying warrants.
Rhea-AI Filing Summary
TransCode Therapeutics, Inc. Schedule 13G/A filed by Anson-related parties reports collective beneficial ownership of 27,125 shares of TransCode common stock, representing 0.1% of the outstanding class when including shares underlying warrants. The reporting group includes Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and principals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the 27,125 shares and no sole voting or dispositive power reported. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control of the issuer.
Positive
- Clear disclosure of beneficial ownership totaling 27,125 shares (0.1%), including shares underlying warrants
- Reporting includes identification of each reporting person, citizenship/place of organization and addresses
Negative
- None.
Insights
TL;DR The disclosed stake is immaterial to control and unlikely to affect TransCode's valuation or governance.
The filing shows a combined beneficial holding of 27,125 shares (0.1%), including shares issuable upon exercise of warrants. For investors, this size is well below thresholds that typically trigger active engagement or reporting changes; the group confirms ordinary-course holding and disclaims an intent to influence control. No changes to sole voting/dispositive power were reported, and the ownership percentage calculation is clearly specified.
TL;DR Ownership is disclosed transparently and does not indicate a governance shift.
The reporting persons are identified with addresses and citizenships, and signatures certify the ordinary-course nature of the holdings. Shared voting and dispositive power is indicated, but the aggregate stake is under 5% and expressly under 1%, so there is no material influence on board control or corporate actions based on this filing alone.
FAQ
What stake does Anson report in TransCode Therapeutics (RNAZ)?
Does the filing indicate sole voting or dispositive power for the reporters?
Who are the reporting parties named in the Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.